Abstract 988P
Background
Liver cancer is a leading cause of cancer-related mortality worldwide. There is a literature gap regarding its burden in the Middle East and North Africa (MENA) region. Therefore, we aimed to investigate the epidemiological trends of primary liver cancer in the MENA region from 1990 to 2019.
Methods
The Global Burden of Disease database was used to extract the age-standardized rates per 100,000 population for prevalence (ASRP), incidence (ASRI), and years lived with disability (YLDs) of primary liver cancer in the MENA region between 1990 and 2019. Data were analyzed to identify regional distribution patterns across different countries and demographic groups using Wilcoxon signed-rank test.
Results
ASRP for liver cancer in the MENA region was significantly higher in 2019 compared to 1990 (median of 4.34 and 5.38 in 1990 and 2019, respectively; P= 0.002). The major causes of primary liver cancer were hepatitis C virus, followed by hepatitis B virus, nonalcoholic steatohepatitis, and alcohol use. In 2019, the highest ASRP was observed in Qatar (24.894; 95% confidence interval (CI): 18.34-33.24) and Egypt (22.575; 95% CI: 16.20-30.90), while Morocco had the lowest one (2.21; 95% CI: 1.68-2.70). On the other hand, no significant increase was observed from 1990 to 2019 for the ASRI (median of 4.26 and 4.49 in 1990 and 2019, respectively, P = 0.498) and YLDs (median of 0.96 and 1.04 in 1990 and 2019, respectively, P = 0.079).
Conclusions
The prevalence of liver cancer shows a rising trend in the MENA region from 1990 to 2019. Adopting regional programs to address the major risk factors should be considered.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
956P - Phase II study of adjuvant tislelizumab combined with interferon-α and active surveillance in hepatocellular carcinoma patients with microvascular invasion
Presenter: Yixiu Wang
Session: Poster session 18
957P - Interim report of Notable-HCC: A phase Ib study of neoadjuvant PD-1 with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma (HCC)
Presenter: Mingming Li
Session: Poster session 18
959P - Combination therapy of envafolimab and suvemcitug in patients with hepatocellular carcinoma (HCC): Results from a phase II clinical trial
Presenter: Lixia Ma
Session: Poster session 18
960P - Personalized circulating tumor DNA (ctDNA) monitoring for recurrence detection and treatment response assessment in hepatocellular carcinoma (HCC)
Presenter: Maen Abdelrahim
Session: Poster session 18
961P - Blood circulating Galectin-3 is a prognostic biomarker in hepatocellular carcinoma
Presenter: Shadi Chamseddine
Session: Poster session 18
962P - SBRT improves the efficacy of immuno-checkpoint inhibitors for hepatocellular carcinoma through the activation of IL-6/JAK1-STAT3/PD-L1 axis mediated by MBD3 degradation
Presenter: Weiwei Yan
Session: Poster session 18
963P - Discovery and validation of cfDNA methylation, AFP and ctDNA mutation for the early detection of hepatocellular carcinoma: A multicenter prospective study (ASCEND-Hep)
Presenter: Mingxin Pan
Session: Poster session 18
966P - Potential role of neuropilin-1 in the prognosis, development and risk of invasion in hepatocellular carcinoma patients
Presenter: Tania Payo-Serafín
Session: Poster session 18